Compare MSGY & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSGY | TCRT |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 4.9M |
| IPO Year | 2024 | 2025 |
| Metric | MSGY | TCRT |
|---|---|---|
| Price | $1.96 | $1.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 9.2K |
| Earning Date | 03-31-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 24.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $1.62 |
| 52 Week High | $22.20 | $4.57 |
| Indicator | MSGY | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 28.45 |
| Support Level | $0.42 | N/A |
| Resistance Level | $3.16 | $2.03 |
| Average True Range (ATR) | 0.56 | 0.10 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 0.25 | 9.30 |
Masonglory Ltd is a a holding company and operates through subsidiary. It is engaged in the provision of wet trades services and other ancillary services as a subcontractor in Hong Kong. As a subcontractor, It provide customers with comprehensive wet trades works solutions, which principally include plastering on floors, ceilings and walls, tile laying on internal and external walls and floors, brick laying, floor screeding, and marble works.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.